RGD肽类肿瘤靶向受体显像的研究现状及前景  

Present and future prospect of studies of the RGD peptide tumor targeting receptor imaging

作　　者：张丽[1] 张春丽[1] 王荣福[1,2] 

机构地区：[1]北京大学第一医院核医学科,北京100034 [2]北京师范大学放射性药物教育部重点实验室,北京100875

出　　处：《中国医学影像技术》2010年第6期1176-1178,共3页Chinese Journal of Medical Imaging Technology

基　　金：放射性药物教育部重点实验室开放基金(0707)

摘　　要：RGD肽是一类含有精氨酸-甘氨酸-天冬氨酸(Arg-Gly-Asp)的小分子多肽,与整合素ανβ3受体有高度的选择性和亲和力。RGD肽与整合素ανβ3受体的特异性结合可介导多种病理生理过程的发生,尤其在肿瘤细胞的黏附、转移和肿瘤新生血管生成中起重要作用。因此,整合素ανβ3受体有望成为新型放射性药物的靶点,而放射性核素标记的RGD肽也可能成为潜在的肿瘤受体显像剂而应用于临床。本文对RGD肽类肿瘤靶向受体显像的研究现状及前景进行综述。RGD peptide is a group of small molecular polypeptide which contains Arg-Gly-Asp triple amino acids,a highly selective and affinitive receptor of integrin ανβ3.Specific binding of RGD peptide and integrin ανβ3 receptor may mediate variety of pathophysiological processes,inhibiting tumor cell adhesion and tumor cell metastasis,especially tumorous angiogenesis.Integrin ανβ3 receptor is expected to become the new target spot of radioactive substances,while the radioactive nuclide labeled RGD peptides will be a potential tumor imaging agent in clinical.The present recent findings and prospects related to the tumor targeting RGD peptide receptor imaging agent were reviewed in this article.

关 键 词：肽类 整联蛋白ανβ3 肿瘤 放射性核素显像 

分 类 号：R817.4[医药卫生—影像医学与核医学]